109 related articles for article (PubMed ID: 29481097)
1. A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931).
Thaisrivongs DA; Morris WJ; Tan L; Song ZJ; Lyons TW; Waldman JH; Naber JR; Chen W; Chen L; Zhang B; Yang J
Org Lett; 2018 Mar; 20(6):1568-1571. PubMed ID: 29481097
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.
Thaisrivongs DA; Miller SP; Molinaro C; Chen Q; Song ZJ; Tan L; Chen L; Chen W; Lekhal A; Pulicare SK; Xu Y
Org Lett; 2016 Nov; 18(22):5780-5783. PubMed ID: 27934506
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
Forman M; Palcza J; Tseng J; Stone JA; Walker B; Swearingen D; Troyer MD; Dockendorf MF
Clin Transl Sci; 2019 Sep; 12(5):545-555. PubMed ID: 31215755
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.
Scott JD; Li SW; Brunskill AP; Chen X; Cox K; Cumming JN; Forman M; Gilbert EJ; Hodgson RA; Hyde LA; Jiang Q; Iserloh U; Kazakevich I; Kuvelkar R; Mei H; Meredith J; Misiaszek J; Orth P; Rossiter LM; Slater M; Stone J; Strickland CO; Voigt JH; Wang G; Wang H; Wu Y; Greenlee WJ; Parker EM; Kennedy ME; Stamford AW
J Med Chem; 2016 Dec; 59(23):10435-10450. PubMed ID: 27933948
[TBL] [Abstract][Full Text] [Related]
5. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
[TBL] [Abstract][Full Text] [Related]
6. Macrocyclic glycopeptide chiral selectors bonded to core-shell particles enables enantiopurity analysis of the entire verubecestat synthetic route.
Barhate CL; Lopez DA; Makarov AA; Bu X; Morris WJ; Lekhal A; Hartman R; Armstrong DW; Regalado EL
J Chromatogr A; 2018 Mar; 1539():87-92. PubMed ID: 29397980
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
Chris Min K; Dockendorf MF; Palcza J; Tseng J; Ma L; Stone JA; Kleijn HJ; Hodsman P; Masuo K; Tanen M; Troyer MD; van Vugt M; Forman MS
Clin Pharmacol Ther; 2019 May; 105(5):1234-1243. PubMed ID: 30347431
[TBL] [Abstract][Full Text] [Related]
8. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D
Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606
[TBL] [Abstract][Full Text] [Related]
9. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors.
Rueeger H; Rondeau JM; McCarthy C; Möbitz H; Tintelnot-Blomley M; Neumann U; Desrayaud S
Bioorg Med Chem Lett; 2011 Apr; 21(7):1942-7. PubMed ID: 21388807
[TBL] [Abstract][Full Text] [Related]
10. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
[TBL] [Abstract][Full Text] [Related]
11. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides.
Rueeger H; Lueoend R; Rogel O; Rondeau JM; Möbitz H; Machauer R; Jacobson L; Staufenbiel M; Desrayaud S; Neumann U
J Med Chem; 2012 Apr; 55(7):3364-86. PubMed ID: 22380629
[TBL] [Abstract][Full Text] [Related]
12. BACE inhibitor bust in Alzheimer trial.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248932
[No Abstract] [Full Text] [Related]
13. Polymer-supported stereoselective synthesis of tetrahydrobenzopyrazino-thiadiazinone dioxides via N-sulfonyl iminiums.
Cankařová N; La Venia A; Krchňák V
ACS Comb Sci; 2014 Jun; 16(6):293-302. PubMed ID: 24575715
[TBL] [Abstract][Full Text] [Related]
14. 2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927.
Dotsenko VV; Chigorina EA; Krivokolysko SG
Expert Opin Ther Pat; 2016 Dec; 26(12):1371-1376. PubMed ID: 27785946
[TBL] [Abstract][Full Text] [Related]
15. Protonation states of the catalytic dyad of β-secretase (BACE1) in the presence of chemically diverse inhibitors: a molecular docking study.
Barman A; Prabhakar R
J Chem Inf Model; 2012 May; 52(5):1275-87. PubMed ID: 22545704
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anti-HIV activity evaluation of novel 2,4-disubstituted 7-methyl-1,1,3-trioxo-2,4-dihydro-pyrazolo-[4,5-e][1,2]thiadiazines.
Liu XY; Yan RZ; Wang Y; Zhan P; De Clercq E; Pannecouque C; Witvrouw M; Molina MT; Vega S
Arch Pharm (Weinheim); 2008 Apr; 341(4):216-22. PubMed ID: 18266290
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
18. A stereoselective approach to peptidomimetic BACE1 inhibitors.
Butini S; Gabellieri E; Brindisi M; Giovani S; Maramai S; Kshirsagar G; Guarino E; Brogi S; La Pietra V; Giustiniano M; Marinelli L; Novellino E; Campiani G; Cappelli A; Gemma S
Eur J Med Chem; 2013; 70():233-47. PubMed ID: 24158015
[TBL] [Abstract][Full Text] [Related]
19. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design.
Hamada Y; Tagad HD; Nishimura Y; Ishiura S; Kiso Y
Bioorg Med Chem Lett; 2012 Jan; 22(2):1130-5. PubMed ID: 22178553
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of aminopyridine derivatives as potential BACE1 inhibitors.
Konno H; Sato T; Saito Y; Sakamoto I; Akaji K
Bioorg Med Chem Lett; 2015 Nov; 25(22):5127-32. PubMed ID: 26459211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
